Equities research analysts at StockNews.com began coverage on shares of Trevena (NASDAQ:TRVN – Get Free Report) in a research report issued on Tuesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.
Trevena Stock Performance
NASDAQ TRVN opened at $0.60 on Tuesday. The business’s 50-day moving average price is $0.63 and its 200 day moving average price is $0.87. Trevena has a twelve month low of $0.51 and a twelve month high of $3.93. The company has a market capitalization of $8.21 million, a PE ratio of -0.13 and a beta of 1.80. The company has a current ratio of 4.03, a quick ratio of 3.92 and a debt-to-equity ratio of 1.45.
Trevena (NASDAQ:TRVN – Get Free Report) last released its earnings results on Monday, August 14th. The biopharmaceutical company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.24). The company had revenue of $3.02 million during the quarter, compared to analysts’ expectations of $0.70 million.
Institutional Investors Weigh In On Trevena
Trevena Company Profile
Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.
- Five stocks we like better than Trevena
- What is the Nikkei 225 index?
- Catch the dip on Sociedad Quimica before earnings?
- How to Buy Bitcoin Stock: 3 Easy Ways to Do It
- Can new GPT store spur generative AI monetization?
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Energy looks to dominate markets with 3 oil and gas stocks
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.